Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Gu Research Network, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,478,927

190 payments

Through program year 2025, Gu Research Network, LLC is reported as receiving $1,478,927 in research payments, across 190 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $221,187 5
2024 Research $414,310 8
2023 Research $113,864 40
2022 Research $190,467 59
2021 Research $222,319 39
2020 Research $217,101 28
2019 Research $99,680 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $414,924 14 payments
  2. Exelixis Inc. $387,291 76 payments
  3. E.R. Squibb & Sons, L.L.C. $290,924 27 payments
  4. AstraZeneca UK Limited $281,669 17 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $80,846 51 payments
  6. Mirati Therapeutics, Inc. $21,999 3 payments
  7. Gilead Sciences, Inc. $925 1 payment
  8. Immunomedics, Inc. $350 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial $355,451 2 payments
  2. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $235,130 44 payments
  3. CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $203,500 3 payments
  4. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $125,412 20 payments
  5. A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer $118,531 7 payments
  6. Phase III Adjuvant Bladder nivo mono $83,770 4 payments
  7. A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer $52,887 8 payments
  8. Darolutamide Roll Over Study $44,667 26 payments
  9. CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease $43,058 2 payments
  10. BAY 1841788, mHSPC $33,594 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record